$80.5 Million Public Offering to Fund Development of Investigational Cancer Treatment
An $80.5 million public offering will support clinical trials, manufacturing and development…
Lacutamab Advances Toward Phase 3 Trial in T-Cell Lymphoma
Sobi and Innate Pharma partner to advance lacutamab into a Phase 3…
Strategic Research Partnership Expands Patient Access to Clinical Trials
A new strategic research partnership aims to expand patient access to clinical…
Major Acquisition to Advance Therapies for Treatment-Resistant Depression
Lilly will acquire AtaiBeckley in a deal valued at up to $3.8…
Global Oncology Pipeline Set to Expand With Next-Generation Cancer Drug Innovation
Novartis will acquire UK-based Myricx Bio in a deal worth up to…
WHO Releases First-Ever Guidance to Advance Child-Focused Dengue Treatments
WHO has released its first-ever guidance to accelerate the development of child-focused…
KFSH Space Medicine Study Ranks Among Top 5% Globally on Altmetric
A KFSH-led study conducted aboard the International Space Station has ranked among…
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Harbour BioMed Announces NMPA Acceptance for the Treatment of Advanced Solid Tumors
Harbour BioMed has announced that China’s National Medical Products Administration (NMPA) has…
